Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

IMMXBullishIndustry Newsnews

High materiality8/10

Immix Biopharma reports 89% CR in AL Amyloidosis; BLA planned mid-2027

Sep 29, 2026, 7:09 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Strong early efficacy signals (89% CR) and potential 98% CR with MRD progress; regulatory path via mid-2027 BLA creates near-term upside if results sustain and no safety concerns emerge.

AI summary

What happened, with direct paths to the underlying reporting

ImmixBiopharma announced interim NEXICART-2 results with an 89% complete response rate across 45 relapsed/refractory AL Amyloidosis patients. All MRD-negative patients progressed to CR within a year, and MRD-negativity in pending cases could lift future CR to 44/45 (98%). Final readout and BLA submission are planned for mid-2027, with a virtual investor event today.

Interim NXC-201 data: 89% CR across 45 AL Amyloidosis patients.
25 new patients: 21 CR, 4 MRD-negative; MRD-negativity may boost CR.
No relapses or neurotoxicity observed to date.
NEXICART-2 final readout and BLA submission planned mid-2027; investor event today.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.